Cargando…

Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study

Prompt cancer diagnosis may align UK survival with European averages. We examined the impact of route to diagnosis on survival for multiple myeloma patients diagnosed 2012–2013 using data from our population‐based patient cohort that links to national death notifications and collects details on trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howell, Debra, Smith, Alexandra, Appleton, Simon, Bagguley, Timothy, Macleod, Una, Cook, Gordon, Patmore, Russell, Roman, Eve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396308/ https://www.ncbi.nlm.nih.gov/pubmed/28146275 http://dx.doi.org/10.1111/bjh.14513

Ejemplares similares

Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)
por: Smith, Alexandra, et al.
Publicado: (2018)

The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research
por: Smith, Alexandra, et al.
Publicado: (2010)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

‘Unpacking’ pathways to lymphoma and myeloma diagnosis: Do experiences align with the Model of Pathways to Treatment? Findings from a UK qualitative study with patients and relatives
por: Howell, Debra, et al.
Publicado: (2020)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials
por: Robinson, Don, et al.
Publicado: (2016)

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma
por: Hájek, Roman, et al.
Publicado: (2019)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Myeloma: Patient accounts of their pathways to diagnosis
por: Howell, Debra A., et al.
Publicado: (2018)

Sotatercept in patients with osteolytic lesions of multiple myeloma
por: Abdulkadyrov, Kudrat M, et al.
Publicado: (2014)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
por: Jakubowiak, Andrzej J., et al.
Publicado: (2019)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
por: Latifoltojar, Arash, et al.
Publicado: (2016)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
por: Gupta, Neeraj, et al.
Publicado: (2016)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers
por: McCaughan, Dorothy, et al.
Publicado: (2022)

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort
por: Lamb, Maxine JE, et al.
Publicado: (2021)

Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network
por: Lamb, Maxine JE, et al.
Publicado: (2019)

Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome
por: Toft‐Petersen, Marie, et al.
Publicado: (2016)

Cohort Profile Update: The Haematological Malignancy Research Network (HMRN) UK population-based cohorts
por: Roman, Eve, et al.
Publicado: (2022)

Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
por: Galleu, Antonio, et al.
Publicado: (2019)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

The long‐term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
por: Else, Monica, et al.
Publicado: (2015)

Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network
por: Howell, Debra A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fenulr6ojhn4ukonarkh3qonog